Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis

NCT ID: NCT03062501

Last Updated: 2017-02-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-30
• Study Completion Date: 2017-07-31

Brief Summary

This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for painful vaso-occlusive crises .

Detailed Description

Sickle cell anemia (SCA) is a hereditary hemoglobinopathy; complications of the disease include, spleen enlargement, acute chest syndrome, pulmonary hypertension, stroke and cumulative damage to multiple organs, and painful vaso-occlusive crises (VOC). In Brazil, about 3,500 children are born each year with DF, and the number of individuals with sickle cell disease (DF) in the country is estimated between 25,000 and 30,000 (ANVISA 2012; BRAZIL, 2012).

Hydroxyurea (HU, or hydroxycarbamide) is the only drug approved to date by the American FDA for use in adults with sickle cell disease. The drug modifies the disease process, improving hematological parameters and the hospitalization time of patients, as well as the frequency of vaso-occlusive crises.In addition to its proven effects during chronic use, experimental data indicate that HU has immediate anti-inflammatory effects.

In addition to its proven effects during chronic use, experimental data indicate that HU has immediate anti-inflammatory effects. This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for VOC.

Conditions

Anemia, Sickle Cell; Anemia; Sickle-Cell, With Crisis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Control (No Hydroxyurea)

Patients in VOC will be treated according to the center's usual practice and analgesia protocol.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Hydroxyurea

Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.

Group Type: EXPERIMENTAL

Hydroxyurea

Intervention Type: DRUG

Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.

Interventions

Hydroxyurea

Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Confirmed diagnosis of homozygous sickle cell anemia (HbSS).
• Hospitalization due to onset of uncomplicated vaso-occlusive crisis (with pain scale≥6 within the last 24 h), confirmed by clinical evaluation.
• Documented and written informed consent

Exclusion Criteria

• Confirmed or suspected pregnancy.
• Initiation of painful crisis> 72h.
• Blood transfusion during the last 8 weeks.
• Admission to Emergency Room due to pain in the last 4 weeks.
• Neutrophil count <2.5 x 109/L or platelet count <95.0 x 109 / L or Hb <4.5 g / dL
• Weight <38 Kg or> 95 Kg.
• Interval longer than 8h since arrival at center.
• Non-consent to participate in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti

OTHER

Sponsor Role: lead

Responsible Party

CLARISSE LOBO

PI

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Hemorio

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status: RECRUITING

Countries

Brazil

Central Contacts

Clarisse Lobo, MD

Role: CONTACT

lobo.clarisse@gmail.com

+ 55 (21) 98133-3606

Facility Contacts

Thais Oliveira, B.Sc.

Role: primary

cdi@hemorio.rj.gov.br

+55 (21) 2505-0750 ext. 2212

Other Identifiers

Hemorio 397/16

Identifier Type: -

Identifier Source: org_study_id